Verastem Stock News

Truist has initiated coverage on Verastem Oncology Inc (NASDAQ: VSTM) with a Buy rating and $6.00 price target, equivalent to approximately 350% upside. Analyst Srikripa Devarakonda notes that trad

Verastem Inc (VSTM) shares closed 2.2% lower than its previous 52 week low, giving the company a market cap of $331M. The stock is currently down 11.2% year-to-date, down 25.7% over the past 12 months, and up 51.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 19.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 49.5% The company's stock price performance over the past 12 months lags the peer average by -358.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Verastem Oncology (VSTM) announces key strategic priorities and upcoming catalysts to support its lead compound VS-6766 in 2022.The company expects to reports results from RAMP 201

Verastem Oncology (VSTM) grants inducement options to purchase 1,625 shares of its common stock and the grant of 813 restricted stock units (RSUs) to two new employees.The options have

Verastem, Inc. (NASDAQ:VSTM) COO Dan Paterson sold 10,994 shares of the stock in a transaction on Monday, December 20th. The stock was sold at an average price of $2.27, for a total value of $24,956.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. []

Brokerages expect Verastem, Inc. (NASDAQ:VSTM) to post ($0.08) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Verastems earnings. Verastem posted earnings per share of ($0.12) during the same quarter last year, which indicates a positive year over year growth rate of 33.3%. The company []

Wall Street analysts expect Verastem, Inc. (NASDAQ:VSTM) to announce earnings of ($0.08) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Verastems earnings. Verastem reported earnings per share of ($0.12) during the same quarter last year, which would suggest a positive year-over-year growth rate of 33.3%. The company []

MetLife Investment Management LLC increased its holdings in shares of Verastem, Inc. (NASDAQ:VSTM) by 172.5% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 65,690 shares of the biopharmaceutical companys stock after purchasing an additional 41,580 shares during the period. MetLife Investment Management LLCs holdings in Verastem were []

Related Stocks: EPZM , MRUS , ADCT , YMAB , MEIP , NTLA , BCRX , CYTK , VSTM , GERN ,

Two new Breakout Stocks for Week 46 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. Following the Daily Momentum Gauges® the portfol

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will present a

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of options to purchase 45

Verastem Oncology has had a relatively quiet year for most of 2021 but a pair of announcements has provided a burst of excitement that could revitalize investor sentiment.

Analysts say these are penny stocks to buy right now. The post Top Penny Stocks To Buy The Dip According To Analysts In September appeared first on Penny Stocks to Buy, Picks, News and Information | P